Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.

Johnson, Martin; Serra Traynor, Carlos; Vishwanathan, Karthick; Overend, Philip; Hartmaier, Ryan; Markovets, Aleksandra; Chmielecki, Juliann; Mugundu, Ganesh M; Barrett, J Carl; Tomkinson, Helen; Ramalingam, Suresh S

Johnson, Martin; Serra Traynor, Carlos; Vishwanathan, Karthick; Overend, Philip; Hartmaier, Ryan; Markovets, Aleksandra; Chmielecki, Juliann; Mugundu, Ganesh M; Barrett, J Carl; Tomkinson, Helen; Ramalingam, Suresh S.

Afiliación

Johnson M; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
Serra Traynor C; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
Vishwanathan K; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Boston, Massachusetts, USA.
Overend P; Oncology Biometrics, Oncology, R&D, AstraZeneca, Cambridge, UK.
Hartmaier R; Translational Medicine, Oncology, R&D, AstraZeneca, Boston, Massachusetts, USA.
Markovets A; Translational Medicine, Oncology, R&D, AstraZeneca, Boston, Massachusetts, USA.
Chmielecki J; Translational Medicine, Oncology, R&D, AstraZeneca, Boston, Massachusetts, USA.
Mugundu GM; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Boston, Massachusetts, USA.
Barrett JC; Translational Medicine, Oncology, R&D, AstraZeneca, Boston, Massachusetts, USA.
Tomkinson H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Science, R&D, AstraZeneca, Cambridge, UK.
Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, USA.

Clin Pharmacol Ther ; 115(2): 349-360, 2024 02.

Article en En | MEDLINE | ID: mdl-38010260

Asunto(s)

Acrilamidas; Compuestos de Anilina; Antineoplásicos; Carcinoma de Pulmón de Células no Pequeñas; ADN Tumoral Circulante; Indoles; Neoplasias Pulmonares; Pirimidinas; Humanos; Antineoplásicos/uso terapéutico; Teorema de Bayes; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Carcinoma de Pulmón de Células no Pequeñas/genética; Carcinoma de Pulmón de Células no Pequeñas/patología; ADN Tumoral Circulante/genética; ADN Tumoral Circulante/uso terapéutico; Progresión de la Enfermedad; Receptores ErbB/genética; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; Mutación; Inhibidores de Proteínas Quinasas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirimidinas / Acrilamidas / Carcinoma de Pulmón de Células no Pequeñas / ADN Tumoral Circulante / Indoles / Compuestos de Anilina / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google